

[全部](#)[新闻](#)[图片](#)[购物](#)[视频](#)[更多](#)[设置](#)[工具](#)

找到约 21,100 条结果 (用时 0.50 秒)

Google 学术 : Management of oligometastatic non-small cell lung cancer patients: current controversies and future directions

... treatment of oligometastatic non-small cell lung cancer - Pfannschmidt - 被引用次数 : 126

... non-small-cell lung cancer (NSCLC): ESMO Clinical ... - Reck - 被引用次数 : 516

... patients with oligometastatic non-small-cell lung cancer ... - Gomez - 被引用次数 : 210

Oligometastatic Non-Small Cell Lung Cancer: A Significant Entity ...

<https://www.karger.com/Article/Fulltext/365634> - 翻译此页

作者 : C Nieder - 2014 - 被引用次数 : 11 - 相关文章

2014年9月3日 - Trends were seen for T stage ($p = 0.058$) and performance status ($p = 0.07$). ... Such studies are also needed to confirm the treatment-dependent survival ... Distant metastatic stage IV non-small cell lung cancer (NSCLC) is a ... We defined oligometastatic disease as in the recent study by Griffioen et al.

Management of patients with brain metastases from non-small cell ...

<https://ro-journal.biomedcentral.com/articles/10.1186/s13014-019-1237-9> ▼ 翻译此页

作者 : C Nieder - 2019

2019年2月15日 - ... from non-small cell lung cancer (NSCLC), patients whose treatment ... brain radiotherapy (WBRT) has become more controversial over the ... Several recent trials, including the randomized QUARTZ trial now ... Research; Open Access Linac Research Consortium, Elekta Spine, Oligometastases and ...

Stereotactic body radiation therapy for lung, spine and oligometastatic ...

<https://www.ncbi.nlm.nih.gov/pubmed/30105233> - 翻译此页

作者 : EM Dunne - 2018 - 被引用次数 : 1 - 相关文章

(1)Department of Radiation Oncology, British Columbia Cancer Agency (BCCA), ... patients with peripherally located stage I non-small cell lung cancer (NSCLC). Controversy remains however as to its efficacy and safety for central or ... the use of SBRT as a novel treatment for spinal metastases and oligometastases is ...



国内版

国际版

Management of oligometastatic non-small cell lung cancer pa



Sign in



All

Images

Videos

翻译成中文

关闭取词

2,040,000 Results

Any time ▾

Managing Patients With Oligometastatic Non–Small-Cell Lung ...

<https://ascopubs.org/doi/10.1200/JOP.2017.026500>

The literature suggests that an **oligometastatic** state exists in **patients** with non–small-cell lung cancer (NSCLC). This observation in the setting of rapidly evolving systemic therapies, including immune checkpoint inhibitors and an increasing number of targeted therapies, represents a ...

Cited by: 10

Author: Sarah Jo Stephens, Michael J. Moravan, ...

Publish Year: 2018

The biology and treatment of oligometastatic cancer

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496163>

Apr 20, 2015 · The evidence for treatment of oligometastases in lung cancer was weak-to-moderate based on the study designs. There were two **nonrandomized** controlled clinical trials (Level 2) [80, 81], however the sample sizes were small (**n = 26 and n = 39**, respectively).

Cited by: 119

Author: Diane K. Reyes, Kenneth J. Pienta

Publish Year: 2015

Local Consolidative Therapy Vs. Maintenance Therapy or ...

<https://ascopubs.org/doi/full/10.1200/JCO.19.00201>

Our previously published findings reported that local consolidative therapy (LCT) with radiotherapy or surgery improved progression-free survival (PFS) and delayed new disease in **patients** with **oligometastatic** non–small-cell lung cancer (NSCLC) that did ...

Cited by: 11

Author: Daniel R. Gomez, Chad Tang, Jianjun Zh...

Publish Year: 2019

27

Name of Journal: World Journal of Clinical Oncology

Manuscript NO: 47622

Manuscript Type: REVIEW

Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions

Couñago F *et al.* Oligometastatic non-small cell lung cancer

Felipe Couñago, Javier Luna, Luis Leonardo Guerrero, Blanca Vaquero, María Cecilia Guillén-Sacoto, Teresa González-Merino, Begoña Taboada, Verónica Díaz, Belén Rubio-Viqueira, Ana Aurora Díaz-Gavela, Francisco José Marcos, Elia del Cerro

Abstract

Oligometastatic non-small cell lung cancer (NSCLC) describes an intermediate stage of NSCLC between localized and widely-disseminated disease. This stage of NSCLC is characterized by a limited number of metastases and a more indolent tumour biology. Currently, the management of oligometastatic NSCLC involves radical treatment (radiotherapy or surgery) that targets the metastatic lesions and the primary tumour to achieve disease control. This approach offers the potential to achieve prolonged survival in patients who, in the past, would have only received palliative measures. The optimal therapeutic strategies for the different scenarios of oligometastatic disease-intracranial *vs* extracranial disease, synchronous *vs* metachronous-remain undefined. Given the lack of head-to-head studies comparing radiotherapy to surgery in these patients, the decision to apply surgery or radiotherapy (with or without systemic treatment) must be based on prognostic factors that allow us to classify patients. This classification will allow us to select the most appropriate therapeutic strategy on an individualized basis. In the future, the molecular or microRNA profiles will likely improve the treatment selection process. The

Match Overview

1	Crossref 139 words Oscar Juan, Sanjay Popat. "Ablative Therapy for Oligom... astatic Non-Small Cell Lung Cancer", Clinical Lung Cance	1%
2	Internet 124 words crawled on 17-Mar-2019 www.medpagetoday.com	1%
3	Internet 114 words crawled on 15-Jun-2019 jtd.amegroups.com	1%
4	Crossref 57 words Qinghua Xu, Fei Zhou, Hui Liu, Tao Jiang, Xuefei Li, Yaping Xu, Caicun Zhou. "Consolidative Local Ablative Therapy I	1%
5	Crossref 49 words Derek P. Bergsma, Joseph K. Salama, Deepinder P. Sing... Steven J. Chmura, Michael T. Milano. "Radiotherapy for Ol	<1%
6	Crossref 48 words Felipe Couñago, Ana Aurora Díaz Gavela, Gemma Sancho , Irene Ortiz et al. "Multiparametric magnetic resonance i...	<1%
7	Crossref 41 words Liza C. Villaruz, Gregory J. Kubicek, Mark A. Socinski. "I... nagement of Non-Small Cell Lung Cancer with Oligometas	<1%
8	Internet 37 words crawled on 24-Jul-2019 cslide.ctimeetingtech.com	<1%
9	Internet 37 words crawled on 07-Nov-2017 link.springer.com	<1%
10	Crossref 31 words	<1%



All

Images

Videos

翻译成中文

关闭取词

2,050,000 Results

Any time ▼

Managing Patients With Oligometastatic Non–Small-Cell ...

<https://ascopubs.org/doi/10.1200/JOP.2017.026500>

The literature suggests that an **oligometastatic** state exists in **patients** with **non–small-cell lung cancer** (NSCLC). This observation in the setting of rapidly evolving systemic therapies, including immune checkpoint inhibitors and an increasing number of targeted ...

Cited by: 11**Author:** Sarah Jo Stephens, Michael J. Moravan, ...**Publish Year:** 2018

The current state of oligometastatic and oligoprogressive ...

<jtd.amegroups.com/article/view/22668/17600> ▼

The **current state of oligometastatic** and **oligoprogressive non-small cell lung cancer** **Oligometastatic disease** is defined as an intermediate state between localized and widespread metastatic disease. Given that in the **oligometastatic state gross tumors** represent the full extent of disease, there may be a role for curative local **therapy** despite **metastatic disease**.

Surgical treatment of oligometastatic non-small cell lung ...

<https://www.sciencedirect.com/science/article/pii/S0169500210002187>

Due to the high number of **patients** included, surgical approaches for **treating pulmonary oligometastatic disease** were evaluated using the landmark studies of IASLC Lung Cancer Staging Project [21] and the SEER program [22] (100,809 and 27,435 **patients**, respectively).

Cited by: 117**Author:** Joachim Pfannschmidt, Hendrik Dienemann**Publish Year:** 2010

Stereotactic radiotherapy in oligometastatic cancer ...

<cco.amegroups.com/article/view/16003/16545> ▼

Gomez DR, Blumenschein GR Jr, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for **patients** with **oligometastatic non-small-cell lung cancer** without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. *Lancet Oncol* 2016;17:1672-82.

Cited by: 2**Author:** Thomas A. G. Kennedy, Mark T. Corkum